Injectable collagenase (CCH) has been clinically tested in twelve indications and is currently marketed for the treatment of Dupuytren's contracture in the U.S., Europe, Canada, Japan and Australia, and for the treatment of Peyronie's disease in the U.S., Canada, Europe and Australia. Injectable collagenase is also currently in clinical development for the potential treatment of a number of medical conditions which have limited or no nonsurgical treatment options, including serious medical conditions.